Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Heart failure in patients treated with bisphosphonates

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Grove, Erik ; Abrahamsen, B ; Vestergaard, P. / Heart failure in patients treated with bisphosphonates. In: Journal of Internal Medicine. 2013 ; Vol. 274, No. 4. pp. 342-50.

Bibtex

@article{ab77e7177b224bb3afefbed2ae3be2e2,
title = "Heart failure in patients treated with bisphosphonates",
abstract = "OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates. DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group. The risk of heart failure was estimated by Cox proportional hazard analyses. RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively. The absolute risk of heart failure was 4.4{\%} in the exposed group and 3.7{\%} in the control group (P ",
author = "Erik Grove and B Abrahamsen and P Vestergaard",
note = "{\circledC} 2013 The Association for the Publication of the Journal of Internal Medicine.",
year = "2013",
month = "10",
doi = "10.1111/joim.12087",
language = "English",
volume = "274",
pages = "342--50",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Heart failure in patients treated with bisphosphonates

AU - Grove, Erik

AU - Abrahamsen, B

AU - Vestergaard, P

N1 - © 2013 The Association for the Publication of the Journal of Internal Medicine.

PY - 2013/10

Y1 - 2013/10

N2 - OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates. DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group. The risk of heart failure was estimated by Cox proportional hazard analyses. RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively. The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P 

AB - OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates. DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group. The risk of heart failure was estimated by Cox proportional hazard analyses. RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively. The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P 

U2 - 10.1111/joim.12087

DO - 10.1111/joim.12087

M3 - Journal article

VL - 274

SP - 342

EP - 350

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 4

ER -

ID: 38706644